Opioid substitution treatment in France: 2023 report

The aim of this report is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.

Comprimés
See the notice on the bibliographic catalog

The first part of the report describes the sociodemographic breakdown of people receiving payment for opioid substitution medications (OSM) in primary care in 2020, as well as their treatment methods. These data come from the simplified generalist sample of recipients (EGBS) of the French National Health Insurance Fund. They are supplemented by the data on prescriptions and supply of OSMs in CSAPA specialised drug treatment centres (2019), data on the prescriptions and supply of OSMs in prisons (2020), and data of sales of OSMs in France (2022).

The second part of the report presents data on misuse, deaths related to OSM drugs, and the sale of naloxone.

Publication type
Briefing papers
Publication date
Language
Français
Author(s)
NDIAYE
Anna
Edited by
OFDT
Number of pages
14
ISBN
979-10-92728-68-2
Products & addictions
Heroin and opioids
Themes
Treatment
Specific population(s)
Adults
People in custody
Territories
France
Dispositif d'enquête et d'observation
Medico-administrative analysis

See also

Drug use in adolescence: trends reported in 2022
  • Alcohol
  • Cannabis
  • e-Cigarette
  • Cocaine and crack
  • GHB and solvents
  • Heroin and opioids
  • Ketamine
  • LSD and mushrooms
  • MDMA/ecstasy and amphetamine
  • Poppers
  • Nitrous oxide
  • Tobacco
Briefing papers
2024
OFDT
17 pages
30 years of penal response to driving under the influence of alcohol or drugs
  • Alcohol
  • Cannabis
  • Cocaine and crack
  • Heroin and opioids
  • MDMA/ecstasy and amphetamine
Tendances
161
2024
OFDT
8 pages
Psychoactive substances, users and markets in France in 2022
  • Benzodiazepines and gabapentinoids
  • Cannabis
  • Cocaine and crack
  • Heroin and opioids
  • Ketamine
  • LSD and mushrooms
  • MDMA/ecstasy and amphetamine
  • New Psychoactive Substances
  • Poppers
  • Nitrous oxide
  • Others
Tendances
160
2023
OFDT
8 pages

Latest publications Briefing papers

All publications Briefing papers
Drug use in adolescence: trends reported in 2022
  • Alcohol
  • Cannabis
  • e-Cigarette
  • Cocaine and crack
  • GHB and solvents
  • Heroin and opioids
  • Ketamine
  • LSD and mushrooms
  • MDMA/ecstasy and amphetamine
  • Poppers
  • Nitrous oxide
  • Tobacco
  • Users
  • France

Psychoactive substance use among middle school and high school students: results of the EnCLASS 2022 survey.

Briefing papers
2024
OFDT
17 pages
Alcohol consumption and its consequences in France in 2022
  • Alcohol
  • Supply and markets
  • Treatment
  • Users
  • France

This report from the French Monitoring Centre for Drugs and Drug Addiction (OFDT) provides an overview of the supply, uses, and the social and health consequences of alcohol consumption in France in 2022

Briefing papers
2023
OFDT
9 pages
The social cost of drugs: an estimation in France in 2019
  • Alcohol
  • Cocaine and crack
  • Heroin and opioids
  • Tobacco
  • Public policy and healthcare provision
  • France

This report presents a new estimate of the social cost of drugs in France in 2019, following a previous calculation in 2010

Briefing papers
2023
OFDT
15 pages
Statistics on people receiving care in specialised drug treatment centres in 2020
  • Alcohol
  • Benzodiazepines and gabapentinoids
  • Cannabis
  • Cocaine and crack
  • GHB and solvents
  • Heroin and opioids
  • Gambling
  • Ketamine
  • LSD and mushrooms
  • MDMA/ecstasy and amphetamine
  • Tobacco
  • Others
  • Treatment
  • France

This report of the RECAP survey (common data collection on addictions and treatments) reviews the main recent changes in the statistics on people with addictive behaviour problems accompanied and cared for by teams from specialised drug treatment centres (CSAPA in French). 

Briefing papers
2023
OFDT
16 pages